Latest news and press releases about TuHURA Biosciences, Inc. (HURA): earnings reports, analyst upgrades/downgrades, product launches, partnerships and regulatory filings. Stay updated on every market-moving event.
TuHURA Biosciences, Inc. is an immuno-oncology firm that has reached the critical Phase 3 registration stage of clinical development. The company is dedicated to pioneering innovative technologies designed to effectively combat the mechanisms by which cancers develop resistance to existing immunotherapy treatments. Its operations are based in Tampa, Florida.
Price
| Price | $2.03 |
| Market Cap | $129M |
| Exchange | NASDAQ |
| Country | US |
Valuation Ratios
| Price / Book | 7.09 |
| EV / EBITDA | -4.38 |
| Dividend Yield | 0.00% |
Profitability
| Return on Equity | -154.32% |
| Return on Invested Capital | -137.40% |
| Return on Assets | -96.49% |
| Gross Margin | 0.00% |
| Operating Margin | 0.00% |
| Net Margin | 0.00% |
Related companies: ABOS · AGEN · CGTX · INO · IRD · MCRB · SEER
Explore sector: Healthcare · Biotechnology
More sections of HURA: Overview · Financials · Valuation · Statistics · Estimates · Technical · Ownership · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks